A contract research organization's response to the new FDA guidances for bioequivalence/bioavailability studies for orally administered drug products.
The new FDA Guidance for Industry BA and BE Studies for Orally Administered Drug Products--General Considerations and Average, Population, and Individual Approaches to Establishing Bioequivalence imply significant changes in the areas of enrollment, cost, ethics, time, entry, validation applications (EVAs), and statistical and pharmacokinetic methods. The changes from three-period to two-period design for food effect studies, the elimination of most steady state studies, and the analyses of only the active moiety or ingredient are welcome. However, if the current guidances are adopted, additional time will be needed for participants, and more participants will be needed, resulting in higher costs to drug developers. The PK parameters needed to assess BE and the need for replicate designs for drugs with long t1/2 are still unclear. Finally, the advantages of the aggregate property of the FDA metric versus the disaggregate criteria are challenged, and four bioequivalence criteria are proposed.
Kimanani
E
E
MDS Pharma Services, Lincoln, Nebraska, USA.
Stypinski
D
D
Curtis
G
G
Stiles
M
M
Heessels
P
P
Logan
S
S
Nelson
K
K
St Germain
E
E
Boswell
G
G
D000284:Administration, Oral; D003284:Contract Services / Q000458:organization & administration*; D003627:Data Interpretation, Statistical; D004341:Drug Evaluation / Q000191:economics / Q000331:legislation & jurisprudence / Q000379:methods / Q000592:standards*; D004345:Drug Industry; D006801:Humans; D010599:Pharmacokinetics; D012107:Research Design; D013997:Time Factors; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence*